CollPlant Biotechnologies annual r&d spending
2017
2018
2019
2020
2021
2022
2023
2024
2025
CollPlant Biotechnologies R&D Spending Growth & History (CLGN)
CollPlant Biotechnologies's r&d spending was $8.2M for fiscal 2025.
View full CollPlant Biotechnologies company overviewCollPlant Biotechnologies annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $8.2M | −$2.3M | −22.14% |
| 2024 | 2024-12-31 | $10.5M | $31,000 | +0.30% |
| 2023 | 2023-12-31 | $10.5M | $229,000 | +2.23% |
| 2022 | 2022-12-31 | $10.3M | $2.6M | +34.39% |
| 2021 | 2021-12-31 | $7.6M | $3.6M | +87.72% |
| 2020 | 2020-12-31 | $4.1M | −$349,000 | −7.91% |
| 2019 | 2019-12-31 | $4.4M | $537,000 | +13.85% |
| 2018 | 2018-12-31 | $3.9M | $3.3M | +563.87% |
| 2017 | 2017-12-31 | $584,000 | — | — |
CollPlant Biotechnologies quarterly r&d spending
Q2.18
Q2.19
Q2.20
Q2.21
Q2.22
Q2.23
Q2.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | $1.7M | −$427,000 | −20.29% |
| Q4 2025 | 2025-12-31 | $2.0M | — | — |
| Q3 2025 | 2025-09-30 | $2.1M | — | — |
| Q2 2025 | 2025-06-30 | $2.0M | −$684,000 | −25.36% |
| Q1 2025 | 2025-03-31 | $2.1M | — | — |
| Q2 2024 | 2024-06-30 | $2.7M | $123,000 | +4.78% |
| Q2 2023 | 2023-06-30 | $2.6M | −$25,000 | −0.96% |
| Q2 2022 | 2022-06-30 | $2.6M | $698,000 | +36.72% |
| Q2 2021 | 2021-06-30 | $1.9M | $899,000 | +89.72% |
| Q2 2020 | 2020-06-30 | $1.0M | −$82,000 | −7.56% |
| Q2 2019 | 2019-06-30 | $1.1M | $443,000 | +69.11% |
| Q2 2018 | 2018-06-30 | $641,000 | — | — |
CollPlant Biotechnologies r&d spending trends
Over the last five fiscal years, CollPlant Biotechnologies's r&d spending increased from $4.1M to $8.2M, a change of $4.1M. The latest reported quarter, Q1 2026, shows $1.7M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review CollPlant Biotechnologies source filings ↗